Kalvista Pharmaceuticals (NASDAQ:KALV) Upgraded to “Buy” by ValuEngine

Kalvista Pharmaceuticals (NASDAQ:KALV) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, February 4th.

A number of other brokerages also recently weighed in on KALV. Zacks Investment Research raised Kalvista Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Wednesday, January 2nd. BidaskClub downgraded Kalvista Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $32.00 target price on shares of Kalvista Pharmaceuticals in a research report on Friday, December 14th. Finally, Jefferies Financial Group began coverage on Kalvista Pharmaceuticals in a research report on Tuesday, October 30th. They issued a “buy” rating and a $30.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.00.

KALV stock opened at $23.39 on Monday. The stock has a market cap of $355.03 million, a price-to-earnings ratio of -15.29 and a beta of 2.38. Kalvista Pharmaceuticals has a 1-year low of $7.73 and a 1-year high of $25.57.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.24. The company had revenue of $5.59 million for the quarter, compared to analyst estimates of $3.70 million. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%. On average, equities analysts predict that Kalvista Pharmaceuticals will post -1.65 EPS for the current year.

In other news, major shareholder Life Sciences Fund Iv (Gp) Sv sold 214,198 shares of the company’s stock in a transaction on Thursday, February 21st. The shares were sold at an average price of $20.55, for a total transaction of $4,401,768.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the stock in a transaction on Monday, January 14th. The shares were sold at an average price of $19.33, for a total value of $193,300.00. Following the completion of the sale, the chief executive officer now owns 272,411 shares of the company’s stock, valued at $5,265,704.63. The disclosure for this sale can be found here. Insiders have sold 271,340 shares of company stock valued at $5,515,620 over the last 90 days. Corporate insiders own 38.40% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Flinton Capital Management LLC bought a new position in shares of Kalvista Pharmaceuticals during the 4th quarter worth about $26,000. Ramsey Quantitative Systems bought a new position in Kalvista Pharmaceuticals in the 4th quarter valued at about $35,000. Bank of Montreal Can bought a new position in Kalvista Pharmaceuticals in the 4th quarter valued at about $90,000. BlackRock Inc. lifted its position in Kalvista Pharmaceuticals by 203.8% in the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 10,871 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Kalvista Pharmaceuticals in the 3rd quarter valued at about $216,000. 74.12% of the stock is currently owned by institutional investors.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Recommended Story: Compound Interest and Why It Matters When Investing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply